Abstract: Systems and methods are provided to ingest data objects from a flat file server for use in one or more system operations including providing a renderable data object to a user and updating a data item database. As described, the ingestion system includes an ingestion module, a flat file module, a compliance module, and a deduplication module wherein the modules together ingest a flat file data object, parse and process a renderable data object from the flat file data object, and store the renderable data object in a renderable object database.

Abstract: Provided herein are methods for the modulation of appearance or material properties within items of apparel or equipment. Also provided herein are design articles having alterable designs.

Abstract: The invention relates to compounds of formula I wherein R1, R2 and - - - - - are as defined herein, pharmaceutical compositions comprising the compounds and methods of treating COVID-19 in a patient by administering therapeutically effective amounts of the compounds and methods of inhibiting or preventing replication of SARS-CoV-2 with the compounds.

Abstract: A group of wells may be located within a region of interest. Multiple scenarios of boundary locations within a group of wells may be obtained. A top-and-base boundary pair, defining a package of interest, may be identified within the individual scenarios of boundary locations. A subsurface property of the package of interest within the individual scenarios of boundary locations may be determined, and the subsurface property of the package of interest within the individual scenarios of boundary locations may be used to determine a subsurface characteristic of the region of interest.

Abstract: A catalyst, useful for oxidative dehydrogenation of ethane, comprising molybdenum, vanadium, tellurium, tantalum, and oxygen, prepared using a stage hydrothermal synthesis procedure, is provided. The catalyst comprises from 30 to 50 wt. % amorphous content and may be combined with a support/carrier material to form a catalyst material. The described catalysts and catalyst materials demonstrate high selectivity for ethylene at higher temperatures, show little to no decline in conversion and selectivity over time, and do not appear to be sensitive to low residual oxygen concentrations.

Abstract: An intermediary well may be selected for a group of wells. The intermediary well may be used as an origin point from which branching wells paths are generated to connect the group of wells through the intermediary well. A shortest path between the intermediary well and the group of wells along the branching well paths may be identified, and the group of wells may be aligned along the shortest path. Boundaries of the intermediary well may be propagated to the aligned group of wells to establish correlation between segments of the intermediary well and segments of the aligned group of wells.

Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: Oxidative dehydrogenation catalysts for converting lower paraffins to alkenes such as ethane to ethylene when prepared as an agglomeration, for example extruded with supports comprising slurries of Nb2O5.

Abstract: Provided in this disclosure are catalyst compositions. The catalyst compositions include an oxidative dehydrogenation catalyst that includes a mixed metal oxide having the empirical formula: Mo1.0V0.12-0.49Te0.05-0.17Nb0.10-0.20AlcOd wherein c is from 0 to 2.0 and d is a number to satisfy the valence of the oxide. The compositions are at least 40 wt. % amorphous as measured by XRD. The disclosure also provides methods of making the compositions.

Abstract: Mixed metal oxide catalysts having an amorphous content of not less than 40 wt. % are prepared by calcining the catalyst precursor fully or partially enclosed by a porous material having a melting temperature greater than 600° C. in an inert container including heating the catalyst precursor at a rate from 0.5 to 10° C. per minute from room temperature to a temperature from 370° C. to 540° C. under a stream of pre heated gas chosen from steam and inert gas and mixtures thereof at a pressure of greater than or equal to 1 psig having a temperature from 300° C. to 540° C. and holding the catalyst precursor at that temperature for at least 2 hours and cooling the catalyst precursor to room temperature.

Abstract: Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Abstract: Mixed metal oxide catalysts having an amorphous content of not less than 40 wt. % are prepared by calcining the catalyst precursor fully or partially enclosed by a porous material having a melting temperature greater than 600° C. in an inert container including heating the catalyst precursor at a rate from 0.5 to 10° C. per minute from room temperature to a temperature from 370° C. to 540° C. under a stream of pre heated gas chosen from steam and inert gas and mixtures thereof at a pressure of greater than or equal to 1 psig having a temperature from 300° C. to 540° C. and holding the catalyst precursor at that temperature for at least 2 hours and cooling the catalyst precursor to room temperature.

Abstract: Disclosed herein are systems and methods for stimulating meibomian gland epithelial cell function by administering to the ocular surface or immediate vicinity of an eye of a subject an effective amount of a pharmaceutical composition containing a PLD-inducing compound, such as the cationic amphiphilic drugs (e.g. azithromycin), androgen or an androgen analogue with androgen effectiveness, corticosteroid, progesterone, IGF-1 or an IGF-1 analogue (e.g. insulin), GH, and mixtures thereof. The pharmaceutical compositions are effective to treat a variety of aliments to the eye including meibomian gland dysfunction, evaporative dry eye disease, lipid abnormalities in meibum or the tear film, and autoimmune diseases such as Sjögren's syndrome.

Abstract: A system and method for forming a scaffolding wherein the system comprises at least one bracket securable to a vertical surface of a building, a horizontal support member supported by the at least one bracket, the support member adapted to support a worker support platform on a horizontal support surface thereof and a flexible retaining member adapted to pass over a worker support platform supported on the horizontal support member so as to retain the worker support platform on the horizontal support surface. The method comprises securing at least one bracket to the a building, supporting a worker support platform on a horizontal support member and retaining the worker support platform on the horizontal support member with the flexible retaining member.

Abstract: Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.

Abstract: This document relates to oxidative dehydrogenation catalysts that include molybdenum, vanadium, and oxygen.

Abstract: Provided in this disclosure are oxidative dehydrogenation catalysts that include a mixed metal oxide having the empirical formula: Mo1.0V0.12-0.49Te0.05-0.17Nb0.10-0.20Od wherein d is a number to satisfy the valence of the oxide. The oxidative dehydrogenation catalyst is characterized by having XRD diffraction peaks (2? degrees) at 22±0.2, 27±0.2, 28.0±0.2, and 28.3±0.1. The disclosure also provides methods of making the catalysts that include wet ball milling.

Abstract: A face-down lounge chair apparatus for comfortable face-down lounging includes a chair frame and a pair of legs coupled to the chair frame. A covering is coupled to the chair frame and has a face aperture extending from a covering top side through a covering bottom side proximal a head distal portion of the chair frame. A face pad is coupled to the covering top side around a perimeter of the face aperture. A drop-down tray is coupled to the covering. The drop-down tray has a plurality of straps coupled to the covering bottom side proximal the face aperture and a tray body adjustably coupled to the plurality of straps to go from a proximal position adjacent the covering to an extended position in parallel opposition to the covering bottom side.

Abstract: This document relates to oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and iron; oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, and aluminum; and oxidative dehydrogenation catalyst materials that include molybdenum, vanadium, oxygen, iron, and aluminum.

Abstract: A method is described for analysis of subsurface data including the use of physics-based modeling and experimental design that allows calculation of probabilities of physical subsurface properties. The method may include calculations of key controlling parameters. The method may include using multiple dimension scaling. The method may be executed by a computer system.